Effects of a drug on aging and Alzheimer's disease
Impact of mammalian target of rapamycin inhibitor therapy on aging-related outcomes
This study is looking at how mTOR inhibitors, like rapamycin, might help people with Alzheimer's and other dementias by possibly extending their lives and improving their health as they age, especially focusing on transplant recipients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10988274 on NIH RePORTER |
What this research studies
This research investigates the impact of mTOR inhibitors, like rapamycin, on aging-related outcomes, particularly focusing on Alzheimer's disease and related dementias. It aims to gather clinical data on whether these therapies can prolong lifespan and improve age-dependent processes in humans. The study will involve a large observational cohort, particularly targeting patients who are transplant recipients, to assess both the benefits and potential risks of mTOR inhibitor therapy. By examining the safety and efficacy of these treatments, the research seeks to fill the gap in understanding their role in aging.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals aged 65 and older, particularly those who are transplant recipients currently receiving mTOR inhibitor therapy.
Not a fit: Patients under the age of 65 or those not receiving mTOR inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for managing aging-related conditions and improving quality of life for older adults.
How similar studies have performed: Previous experimental studies have shown promising results with mTOR inhibitors in extending lifespan and preventing Alzheimer's disease progression, but clinical data in humans is limited.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Bittermann, Therese — University of Pennsylvania
- Study coordinator: Bittermann, Therese
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.